EUVIMEDEUVIMED entdecken
Crossref

NGS versus exome versus genome wide: Advantages? Disadvantages?

Anne Barlier, Jérôme Bouligand

Annales d'Endocrinologie · 2026-04 · 87 (2) · 102508

DOI: 10.1016/j.ando.2026.102508 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annales d'Endocrinologie, 2026-04. Verfasst von Anne Barlier und 1 weiteren Autor:innen. Beteiligte Einrichtung: Aix Marseille Univ, APHM, INSERM, MMG, MarMaRa institute, La Timone University Hospital, Laboratory of Molecular Biology GEnOPé, BIOGENOPOLE, Marseil…. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Assistance Publique - Hopitaux de Paris, République Française Ministère de la Santé et des Sports.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The technical development of automated Sanger sequencing in the 2000s followed by next-generation sequencing (NGS) in the 2010s, has enabled significant advancements in the molecular diagnosis of inherited diseases. The launch of France's first National Rare Diseases Plan in 2011 further supported the establishment of rare disease centers and networks of rare diseases. Concurrently, NGS platform were integrated into molecular biology laboratories, enabling the first diagnoses using Targeted Exome Sequencing (TES) (gene panel). These approaches have been progressively implemented at very high throughput, evolving from Whole Exome Sequencing (WES, which analyzes all coding regions of the human genome) to Whole Genome Sequencing (WGS), the latter being integrated into the France Genomic Medicine 2025 plan initiated in 2016. In this review, we compare TES, WES, and WGS, and discuss their respective advantages, limitations, and future prospects, as well as their applications in the field of endocrinology.

Schlagwörter

Stichwörter der Autor:innen

ExomeGenomeSequencing NGS

Autor:innen und Institutionen

  • Aix Marseille Univ, APHM, INSERM, MMG, MarMaRa institute, La Timone University Hospital, Laboratory of Molecular Biology GEnOPé, BIOGENOPOLE, Marseille, France. Electronic address: Anne.barlier@univ-amu.fr.
  • Service de Médecine Génomique et Pharmacogénomique and Inserm unit 1185, Hôpitaux Universitaires Paris-Saclay, Assistance Publique-Hôpitaux de Paris, Hôpital de Bicêtre, 94275 Le Kremlin Bicêtre, France. Electronic addr…

Förderung

  • Assistance Publique - Hopitaux de Paris
  • République Française Ministère de la Santé et des Sports

Zitieren

APA

Barlier, A., & Bouligand, J. (2026). NGS versus exome versus genome wide: Advantages? Disadvantages?. Annales d'Endocrinologie, 87(2), 102508. https://doi.org/10.1016/j.ando.2026.102508

Vancouver

Barlier A, Bouligand J. NGS versus exome versus genome wide: Advantages? Disadvantages?. Annales d'Endocrinologie. 2026;87(2):102508. doi:10.1016/j.ando.2026.102508

BibTeX
@article{Barlier2026,
  author = {Barlier, Anne and Bouligand, Jérôme},
  title = {NGS versus exome versus genome wide: Advantages? Disadvantages?},
  journal = {Annales d'Endocrinologie},
  year = {2026},
  volume = {87},
  number = {2},
  pages = {102508},
  doi = {10.1016/j.ando.2026.102508}
}
Kostenlos starten →